• United Therapeutics Chairperson and CEO Martine A. Rothblatt exercised stock options for 9,500 shares on July 10, 2026 at USD 135.42.
• Rothblatt sold 9,500 shares the same day in multiple trades at weighted-average prices of about USD 540.37 to USD 553.47.
• Direct common stock holdings ended at 40,513 shares.
• Directly held stock options ended at 20,718.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000096), on July 13, 2026, and is solely responsible for the information contained therein.